CompletedNot Applicable

Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer

United States41 participantsStarted 2015-06

Plain-language summary

This pilot research trial studies continuous activity monitoring during fractionated radiotherapy in patients with head and neck, lung, or gastrointestinal cancer. This study explores the use of fitness trackers to study the activity levels of patients before, during, and after radiation therapy and the use of weekly assessments to measure the patients' quality of life during radiation therapy. This may allow doctors to see if there is any relationship between activity levels, quality of life, treatment interruptions, hospitalizations, and clinical outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Able to ambulate independently (without the assistance of a cane or walker) * Diagnosis of invasive malignancy of the head and neck region, lung, or gastrointestinal tract * Planned treatment with fractionated (\>= 15 treatments) external beam radiotherapy with concurrent chemotherapy with curative intent * Women of childbearing potential must: * Have a negative serum or urine pregnancy test within 72 hours prior to the start of study therapy * Agree to utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study therapy is completed * Be advised of the importance of avoiding pregnancy during trial participation and the potential risks of an unintentional pregnancy * All patients must sign study specific informed consent prior to study entry

What they're measuring

Number of patients who complete most (>= 80%) of the protocol-specified assessments

Timeframe: Up to 4 weeks post-chemoradiation therapy

Number of patients who successfully use the activity monitor (i.e. wearing the activity monitor throughout the treatment course)

Timeframe: Up to 4 weeks post-chemoradiation therapy

Trial details

NCT IDNCT02649569

SponsorMontefiore Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-07

View on ClinicalTrials.gov More Digestive System Carcinoma trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of patients who complete most (>= 80%) of the protocol-specified assessments

Timeframe: Up to 4 weeks post-chemoradiation therapy

Number of patients who successfully use the activity monitor (i.e. wearing the activity monitor throughout the treatment course)

Timeframe: Up to 4 weeks post-chemoradiation therapy